FDA staff says BiDil cuts deaths among black heart patients

06/16/2005 | Reuters

An FDA staff analysis says NitroMed's heart-failure drug BiDil significantly reduced deaths and hospitalizations among blacks in a clinical study, and it should be indicated for treatment of black patients. The staff report was released in advance of today's FDA advisory panel meeting to decide if BiDil should become the first drug approved for treatment of a specific racial group.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park